Zacks Research Brokers Reduce Earnings Estimates for Sanofi

Sanofi (NASDAQ:SNY) – Research analysts at Zacks Research dropped their Q2 2026 EPS estimates for Sanofi in a research report issued on Thursday, December 11th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.09 for the quarter, down from their prior forecast of $1.10. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q1 2027 earnings at $1.11 EPS.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same period last year, the firm posted $2.25 earnings per share. The business’s revenue was down 7.5% on a year-over-year basis.

A number of other equities analysts also recently issued reports on the company. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. HSBC reiterated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Stock Down 1.8%

NASDAQ SNY opened at $47.82 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.30. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The stock has a market capitalization of $117.42 billion, a PE ratio of 11.20, a PEG ratio of 1.33 and a beta of 0.44. The business has a fifty day moving average price of $49.83 and a two-hundred day moving average price of $48.99.

Institutional Investors Weigh In On Sanofi

Several institutional investors have recently bought and sold shares of the stock. Capital Analysts LLC increased its position in shares of Sanofi by 14.0% during the first quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after acquiring an additional 204 shares during the last quarter. Advisory Services Network LLC raised its stake in shares of Sanofi by 1.4% during the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares during the period. Thomasville National Bank boosted its holdings in shares of Sanofi by 0.3% in the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after buying an additional 211 shares during the last quarter. Waterfront Wealth Inc. grew its position in Sanofi by 0.4% during the third quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after buying an additional 214 shares during the period. Finally, HighPoint Advisor Group LLC increased its holdings in Sanofi by 2.3% during the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after buying an additional 226 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.